Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - News - Pharmaceutical Development - August 22, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/15/17 - A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability,...
By a News Reporter-Staff News Editor at China Weekly News Staff editors report on the newly launched clinical trial, NCT03237156, which has the following summary description: "The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male
8/15/17 - Access Scientific Launches High-Flow, Single-Lumen Central Line
When central venous access for high-flow fluid resuscitation and drug administration is urgent, Access Scientific now has the answer the POWERWAND? CVC. Recently cleared by FDA for central venous access, this 16 gauge, single-lumen POWERWAND can be inserted, using the proprietary Accelerated Seldinger Technique, in literally seconds faster
8/15/17 - Allakos Announces Additions to Senior Leadership Team
Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced the appointments of two industry veterans to the leadership team. Robert Alexander, former Chief Executive Officer of ZS Pharma, has been...
8/15/17 - CEL SCI CORP FILES (8-K) Disclosing Other Events
On August 14, 2017 the Company announced it has received a letter from the U.S. Food and Drug Administration stating that the clinical hold that had been imposed on the Company's Phase 3 cancer study with Multikine has been removed and that all clinical trial activities under this Investigational New Drug application may resume. On August 14, 2017
8/15/17 - Clinical trial uses a genetically engineered virus to fight cancer
Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors. The Phase I immunotherapy trial is for those ages 18 and older with metastatic solid tumors that have not responded to standard treatments. The treatment injects an oncolytic virus ve
8/15/17 - Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection
Cocrystal Pharma, Inc., a clinical stage biopharmaceutical company focused on developing innovative antiviral therapeutics, today announced the successful completion and positive data from the Phase 1 a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus- infected individuals. CC-31244 is a...
8/15/17 - Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update
Release date- 14082017- NORWOOD, MA- Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the second quarter ended June 30, 2017. 'We have made significant progress on the corporate, operational and clinical fro
8/15/17 - Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI2 Trial in Gynecological Malignancies
Release date- 14082017- London, Ontario and Boston, MA- Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has completed the dose escalation portion of its Phase 1 study of COTI-2 in women with advanced gynecologic cancers who
8/15/17 - CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in Smokeless Tobacco Addiction
CV Sciences, Inc. highlighted a recent study conducted at Federal University of Prana and Santa Catarina in Brazil which reports that preclinical and clinical studies suggested that cannabidiol may help prevent drug addiction relapse. CV Sciences is pioneering the development of a synthetic, pharmaceutical-grade CBD as an adjunct to nicotine...
8/15/17 - Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
Release date- 14082017- PALO ALTO, Calif.- Eiger BioPharmaceuticals Inc., focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months and six months ended June 30, 2017 and provided a business update. 'We continue to advance our pipeline of novel treatments for orp
8/15/17 - ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017
HOUSTON, TX and VANCOUVER, Aug. 14, 2017/ PRNewswire/- ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the fiscal third quarter ended June 30, 2017 and progress on its clinical development program. "We continue to treat patients with EPI-506 i
8/15/17 - FDA approves emergency use declaration for multiplex Zika test
The FDA made the authorization for CII-ArboViroPlex rRT-PCR Test developed by the Center for Infection and Immunity, or CII, at Columbia University's Mailman School of Medicine Monday. "The FDA decision to issue the EUA gives clinicians and researchers a powerful tool to diagnose and prevent the spread of Zika," W. Ian Lipkin, director of CII and
8/15/17 - FDA Confirms IND Application From VBI Vaccines
VBI Vaccines announced the US Food and Drug Administration accepted their Investigational New Drug Application for VBI-1901, an immunotherapy against brain tumor Glioblastoma Multiforme. A growing body of research has demonstrated that GBM tumors may be susceptible to infection by CMV, with over 90% of GBM tumors expressing CMV antigens, said
8/15/17 - FDA Grants Genentech's Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
By a News Reporter-Staff News Editor at Cancer Weekly Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company's supplemental New Drug Application and granted Priority Review for Alecensa as an initial treatment for people with anaplastic lymphoma kinase- positive, locally advanced o
8/15/17 - Galena Biopharma Reports Second Quarter 2017 Financial Results
'Last week we made a transformative announcement to merge with SELLAS Life Sciences Group in what we believe is the best option for our stockholders,' said Stephen F. Ghiglieri, Interim Chief Executive Officer and Chief Financial Officer.' We reached out to hundreds of companies through our financial advisor during our review of strategic alternati
8/15/17 - Gilead Announces U.S. FDA Priority Review Designation for Fixed Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Release date- 14082017- FOSTER CITY, Calif.- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review for the company's New Drug Application for an investigational, fixed dose combination of bictegravir, a novel investigational integrase strand transfer inhibitor, and emtricitabine/tenofovir...
8/15/17 - Glycobiology Market Is Expected To Drive The Growth Due To Technological Advancements in Glycomics Instruments Till 2025: Grand View Research, Inc.
According to the report published by Grand View Research, Global Glycobiology Market size was estimated at USD 645.7 million in 2016 and Increasing investment in R&D by research institutes and pharmaceutical& biotechnology companies has been a major factor driving market growth. Global Glycomics/Glycobiology Market is expected to reach USD 2.1 bill
8/15/17 - Health Canada Approves OCREVUS (ocrelizumab) for Canadians Living with Relapsing-Remitting Multiple Sclerosis (RRMS)
-Hoffmann-La Roche Limited today announced that Health Canada has approved OCREVUS? for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical and imaging features. 2 The approval of OCREVUS is based on the pivotal phase III, OPERA I& II studies, in which safety and efficacy were evalua
8/15/17 - Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study
Press Release 15 August 2017 Immunicum AB Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study Immunicum AB, a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the last patient last visit in the ongoing Phase I/II study of ilixadencel in...
8/15/17 - Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury's NewsMakers Conference
Innovation Pharmaceuticals,, a clinical stage biopharmaceutical company, today announced that the Company will present a corporate overview at BioCentury s 24th Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY.. We will also highlight the major events upcoming for us in the fourth quarter, n
8/15/17 - Ionis to Independently Advance Inotersen and IONIS FB L Rx
Release date- 14082017- CARLSBAD, Calif.- Ionis Pharmaceuticals Inc. today reported that the Company has retained all rights to inotersen and IONIS-FB-LRx. We are prepared to independently advance inotersen and remain on track to file for marketing approval of inotersen in the U.S. and EU this year,' said B. Lynne Parshall, chief operating officer
8/15/17 - Is FDA Taking Close Enough Look at Fast-Tracked Drugs?
Medications fast-tracked to market under the U.S. Food and Drug Administration's "accelerated approval" process are not receiving proper follow-up clinical trials that are required to confirm their benefits, one study reported. Aaron Kesselheim, an associate professor at Harvard Medical School. Joseph Ross, an assistant professor with Yale School o
8/15/17 - Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Lexicon Pharmaceuticals, Inc. announced today additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor. These results of the inTandem2 study, conducted primarily in Europe, replicated results previously reported from Lexicon's Phase 3 inTandem1 study of sotagliflozin in
8/15/17 - Lipocine Announces FDA Acknowledgement of TLANDO NDA Resubmission; PDUFA Goal Date, February 8, 2018
Release date- 14082017- SALT LAKE CITY- Lipocine Inc., a specialty pharmaceutical company, today announced that the U.S. Food& Drug Administration has acknowledged receipt of the Company's New Drug Application resubmission for TLANDO, its oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associat
8/15/17 - Medtronic Announces Randomized Global Resolute Onyx DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology
Release date- 14082017- DUBLIN- Medtronic plc today announced a global randomized clinical trial that will evaluate one month dual antiplatelet therapy the combination of aspirin and an anticlotting medication in patients implanted with the Resolute Onyx Drug Eluting Stent during percutaneous coronary intervention. The study further demonstrates th
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415